Mechelen, Belgium; 13 November 2019; 22.01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received a transparency notification from Gilead Sciences, Inc.
Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on 11 November 2019 from Gilead Sciences, Inc. (acting as a parent undertaking or a controlling person), who notified that Gilead Therapeutics A1 Unlimited Company, an indirect subsidiary of Gilead Sciences, Inc., holds 16,207,477 of Galapagos' voting rights, consisting of 16,207,477 shares, as a result of subscribing to a capital increase in the framework of the exercise of the Initial Warrant A and thus receiving 2,617,791 new Galapagos shares on 6 November 2019. This represents 25.10% of Galapagos' currently outstanding 64,571,622 shares. Gilead Therapeutics A1 Unlimited Company thus crossed above the 25% threshold of Galapagos' voting rights by acquisition of voting securities on 6 November 2019.
The notification specifies furthermore that (i) Gilead Therapeutics A1 Unlimited Company is a direct subsidiary of Gilead Biopharmaceutics Ireland UC, (ii) Gilead Biopharmaceutics Ireland UC is a direct subsidiary of Gilead Sciences, Inc., and (iii) Gilead Sciences, Inc. has no controlling shareholder.
The full transparency notification is available on the Galapagos website.
About Galapagos
Galapagos ((Euronext &, NASDAQ:GLPG) discovers and develops small molecule medicines with novel modes of action, three of which show promising patient results and are currently in late-stage development in multiple diseases. The Company's pipeline comprises Phase 3 through to discovery programs in inflammation, fibrosis, osteoarthritis and other indications. Galapagos' ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at www.glpg.com.
Galapagos Contacts | |
Investors: | Media: |
Elizabeth Goodwin | Carmen Vroonen |
VP Investor Relations | Senior Director Communications |
+1 781 460 1784 | +32 473 824 874 |
Sofie Van Gijsel | Evelyn Fox |
Director Investor Relations | Director Communications |
+32 485 19 14 15 | +31 6 53 591 999 |
ir@glpg.com | communications@glpg.com |
1 Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions.
Attachment
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.